Intranasal Naloxone
(NS-001)

Access to naloxone is a priority for reducing opioid deaths. Intranasal Naloxone aimed at assisting in acute emergency situations like opioid overdose. 

nasusphrma taffix

Medical need

In 2017 ~72000 overdose death in the USA~42000 from opioids.

Regulatory requirements

Bioequivalence study –”equal or better”

nasusphrma taffix
nasusphrma taffix
nasusphrma taffix

Pilot Study

nasusphrma taffix
nasusphrma taffix

The peak systemic exposure was approximately

1.6 fold higher

The partial AUC0-4 minutes was approximately​

7 fold higher

The partial AUC0-10 minutes was approximate

4 fold higher 

The partial AUC10-30 minutes was approximate

1.6 fold higher

The total systemic exposure was approximate

1.26 fold higher

The median Tmax occurred approximately

5 minutes earlier

Contact us for more information

To request more information , please submit your contact details below: